Clinical evidence indicates that the administration of selective serotonin reuptake inhibitors, such as sertraline-related compounds, impacts immunological parameters and white blood cell counts.
The claim specifically asserts that sertraline administration impacts white blood cell counts and immunological parameters. Paper [1] demonstrates that selective serotonin reuptake inhibitors (SSRIs) significantly reduce white blood cell counts and inflammatory markers. Paper [7] confirms the general immunomodulatory effects of SSRIs. No papers refute the claim, leading to a SUPPORTED verdict.